Parasitic lung infections

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 3, 2009, Pages 274-282

  Vijayan, Vannan Kandi ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Babesiosis; Malaria; Paragonimiasis; Parasitic pneumonias; Strongyloidiasis; Tropical pulmonary eosinophilia

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ANTIPARASITIC AGENT; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; BITHIONOL; CLINDAMYCIN; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MEBENDAZOLE; MEFLOQUINE; METRONIDAZOLE; MILTEFOSINE; NICLOFOLAN; PENTAMIDINE; PRAZIQUANTEL; PYRIMETHAMINE SULFADIAZINE; QUININE; TIABENDAZOLE; TINIDAZOLE; TRICLABENDAZOLE; IMMUNOSUPPRESSIVE AGENT;

ACANTHAMOEBA; AMEBIASIS; ANCYLOSTOMA DUODENALE; ANCYLOSTOMIASIS; ASCARIASIS; ASCARIS LUMBRICOIDES; BABESIOSIS; BALAMUTHIA INFECTION; BALANTIDIASIS; BRUGIA MALAYI; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOSPORIDIOSIS; DIROFILARIA IMMITIS; DIROFILARIA REPENS; DIROFILARIASIS; ECHINOCOCCUS GRANULOSUS; ENTAMOEBA HISTOLYTICA; FILARIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIA DONOVANI; LEISHMANIASIS; LOEFFLER PNEUMONIA; LUNG HYDATID CYST; LUNG INFECTION; MALARIA; NECATOR AMERICANUS; PARAGONIMIASIS; PARAGONIMUS WESTERMANI; PARASITIC LUNG DISEASE; PARASITOSIS; PLASMODIUM FALCIPARUM; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; SINGLE DRUG DOSE; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; THORAX RADIOGRAPHY; TOXOCARA CANIS; TOXOCARIASIS; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRICHINELLA SPIRALIS; TRICHINOSIS; TRYPANOSOMIASIS; WUCHERERIA BANCROFTI; GREENHOUSE EFFECT; IMMUNE DEFICIENCY; OPPORTUNISTIC INFECTION; PARASITOLOGY; PREVALENCE; RISK FACTOR;

ANTIPARASITIC AGENTS; GREENHOUSE EFFECT; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, PARASITIC; OPPORTUNISTIC INFECTIONS; PREVALENCE; RISK FACTORS;

EID: 67649216905     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328326f3f8     Document Type: Review

References (74)

1. Vijayan VK. Tropical parasitic lung diseases. Indian J Chest Dis Allied Sci 2008; 50:49-66.
2. Roy S, Herwaldt B. Prevention of specific infectious diseases: amebiasis. In: Arguin PM, Kozarsky PE, Reed C, editors. CDC Health Information for International Travel 2008. Atlanta: Centres for Disease and Control; 2008. http://wwwn.cdc.gov/travel/yellowBook.aspx. [Accessed 18 October 2008]
3. Vijayan VK. How to diagnose and manage common parasitic pneumonias. Curr Opin Pulm Med 2007; 13:218-224.
4. Ackers JP, Mirelman D. Progress in research on Entamoeba histolytica pathogenesis. Curr Opin Microbiol 2006; 9:367-373.
5. Hsu MS, Hsieh SM, Chen MY, et al. Association between amebic liver abscess and human immunodeficiency virus infection in Taiwanese subjects. BMC Infect Dis 2008; 8:48; doi: 10.1 186/1471-2334-8-48.
6. Shamsuzzaman SM, Hashiguchi Y. Thoracic amoebiasis. Clin Chest Med 2002; 23:479-492.
7. Bansal D, Malla N, Mahajan RC. Drug resistance in amoebiasis. Indian J Med Res 2006; 123:115-118.
8. Leon-Sicairos N, Reyes-Lopez M, Ordaz-Pichardo C, de la Garza M. Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica. Biochem Cell Biol 2006; 84:327-336.
9. Muneizel S, Halasah N, Yassin M. Nitroimidazoles in the treatment of intestinal amoebiasis. Middle East J Fam Med 2008; 6:6-8.
10. Piscopo TV, Mallia AC. Leishmaniasis. Postgrad Med J 2006; 82:649-657.
11. Morales P, Torres JJ, Salavert M, et al. Visceral leishmaniasis in lung transplantation. Transplant Proc 2003; 35:2001-2003.
12. Deborggraeve S, Laurent T, Espinosa D, et al. A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J Infect Dis 2008; 198:1565-1572.
13. Deborggraeve S, Boelaert M, Rijal S, et al. Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease. Trop Med Int Health 2008; 13:1378-1383.
14. Islam MZ, Itoh M, Takagi H, et al. Enzyme-linked immunosorbent assay to detect urinary antibody against recombinant rKRP42 antigen made from Leishmania donovani for the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2008; 79:599-604.
15. Croft SL, Engel J. Miltefosine: discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100 (Suppl 1): 54-58.
16. Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008; 358:1805-1810.
17. Tan LK, Yacoub S, Scott S, et al. Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis 2008; 8:449-454.
18. Francischetti IM. Does activation of the blood coagulation cascade have a role in malaria pathogenesis. Trends Parasitol 2008; 24:258-263.
19. Mharakurwa S, Simoloka C, Thuma PE, et al. PCR detection of Plasmodium falciparum in human urine and saliva samples. Malar J 2006; 5:103; doi: 10.1186/1475-2875-5-103.
20. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008; 358:1829-1836.
21. Praygod G, De Fray A, Eisenhut M. Artemisin derivatives versus quinine in treating severe malaria in children: a systematic review. Malar J 2008; 7:210.
22. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organisation; 2006. pp. 1-266.
23. Talwar A, Fein AM, Ahluwalia G. Pulmonary and critical care aspects of severe malaria. In: Sharma OP, editor. Lung biology in health and disease: tropical lung diseases, 2nd ed. New York: Taylor & Francis Group; 2006. pp. 255-279.
24. Freedman DO. Clinical practice: malaria prevention in short-term travelers. N Engl J Med 2008; 359:603-612.
25. Hassan Sel-D, Malik EM, Okoued SI, Eltayeb EM. Retention and efficacy of long-lasting insecticide-treated nets distributed in eastern Sudan: a two-step community-based study. Malar J 2008; 7:85; doi: 10.1186/1475-2875-7-85.
26. Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am 2008; 22:469-488.
27. Genchi C. Human babesiosis: an emerging zoonosis. Parassitologia 2007; 49 (Suppl 1):29-31.
28. Cirino CM, Leitman SF, Williams E, et al. Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. Ann Intern Med 2008; 148:794-795.
29. Boustani MR, Lepore TJ, Gelfand JA, Lazarus DS. Acute respiratory failure in patients treated for babesiosis. Am J Respir Crit Care Med 1994; 149:1689-1691.
30. Florescu D, Sordillo PP, Glyptis A, et al. Splenic infarction in human babesiosis: two cases and discussion. Clin Infect Dis 2008; 46:e8-e11.
31. Kuwayama DP, Briones RJ. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect Dis 2008; 46:e92-e95.
32. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370-376.
33. Raju M, Salazar JC, Leopold H, Krause PJ. Atovaquone and azithromycin treatment for babesiosis in an infant. Pediatr Infect Dis 2007; 26:181-183.
34. Dodds EM. Toxoplasmosis. Curr Opin Ophthalmol 2006; 17:557-561.
35. Pepper M, Dzierszinski F, Wilson E, et al. Plasmacytoid dendritic cells are activated by Toxoplasma gondii to present antigen and produce cytokines. J Immunol 2008; 180:6229-6236.
36. Nash G, Kerschmann RL, Herndier B, Dubey JP. The pathological manifestations of pulmonary toxoplasmosis in the acquired immunodeficiency syndrome. Hum Pathol 1994; 25:652-658.
37. Petersen E, Edvinsson B, Lundgren B, et al. Diagnosis of pulmonary infection with Toxoplasma gondii in immunocompromised HIV-positive patients by realtime PCR. Eur J Clin Microbiol Infect Dis 2006; 25:401-404.
38. Contini C. Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient. Parassitologia 2008; 50:45-50.
39. Cuppari AF, Sanchez V, Ledesma B, et al. Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2008; 26:5040-5045. This study demonstrates that TgPI-1 elicits strong specific immune response, making it a good candidate in a vaccine against toxoplasmosis.
40. Gottstein B, Reichen J. Hydatid lung disease (echinococcosis/hydatidosis) . Clin Chest Med 2002; 23:397-408.
41. Kuzucu A. Parasitic diseases of the respiratory tract. Curr Opin Pulm Med 2006; 12:212-221.
42. Fanne RA, Khamaisi M, Mevorach D, et al. Spontaneous rupture of lung echinococcal cyst causing anaphylactic shock and respiratory distress syndrome. Thorax 2006; 61:550.
43. Kilic D, Findikcioglu A, Kocer E, Hatipoglu A. Unusual manifestation of bronchiolitis obliterans organizing pneumonia. Acta Chir Belg 2008; 108:468-470.
44. Reuter S, Grüner B, Buck AK, et al. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin 2008; 47:147-152.
45. Kavukcu S, Kilic D, Tokat AO, et al. Parenchyma-preserving surgery in the management of pulmonary hydatid cysts. J Invest Surg 2006; 19:61-68.
46. Haralabidis S, Diakou A, Frydas S, et al. Long-term evaluation of patients with hydatidosis treated with albendazole and praziquantel. Int J Immunopathol Pharmacol 2008; 21:429-435.
47. Gottstein B, Reichen J. Hydatid lung disease. In: Sharma OP, editor. Lung biology in health and disease: tropical lung disease, 2nd ed. New York: Taylor & Francis Group; 2006. pp. 327-350.
48. Doherty JF, Moody AH, Wright SG. Katayama fever: an acute manifestation of schistosomiasis. Br Med J 1996; 313:1071-1072.
49. Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218-224.
50. Lambertucci JR, Silva LC, de Queiroz LC. Pulmonary nodules and pleural effusion in the acute phase of schistosomiasis mansoni. Rev Soc Bras Med Trop 2007; 40:374-375.
51. Lapa MS, Ferreira EV, Jardim C, et al. Clinical characteristics of pulmonary hypertension patients in two reference centres in the city of Sao Paulo. Rev Assoc Med Bras 2006; 52:139-143.
52. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007; 8:105-116.
53. Touré S, Zhang Y, Bosqué-Oliva E, et al. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso. Bull World Health Organ 2008; 86: 780-787.
54. Strobel M, Veasna D, Saykham M, et al. Pleuro-pulmonary paragonimiasis. Med Mal Infect 2005; 35:476-481.
55. Zarrin-Khameh N, Citron DR, Stager CE, Laucirica R. Pulmonary paragonimiasis diagnosed by fine-needle aspiration biopsy. J Clin Microbiol 2008; 46:2137-2140.
56. Lee JS, Lee J, Kim SH, Yong TS. Molecular cloning and characterization of a major egg antigen in Paragonimus westermani and its use in ELISA for the immunodiagnosis of paragonimiasis. Parasitol Res 2007; 100:677-681.
57. Keiser J, Engels D, Buscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14:1513-1526.
58. Belizaro VY, Amarillo ME, de Leon WU, et al. A comparison of the efficacy of single dose of albendazole, ivermectin and diethylcarbamazine alone or in combination against Ascaris and Trichuris spp. Bull World Health Organ 2003; 81:35-42.
59. Gorman SR, Craven DE. Images in clinical medicine. Strongyloides stercoralis hyperinfection. N Engl J Med 2008; 359:e12.
60. Ghoshal UC, Ghoshal U, Jain M, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 2002; 17:1331-1333.
61. Janssen R, Vlaminckx BJM, Seldenrijk CA, et al. Strongyloides stercoralis hyperinfection mimicking accelerated form of idiopathic pulmonary fibrosis. Lancet Infect Dis 2008; 8:456.
62. Vijayan VK. Immunopathogenesis and treatment of eosinophilic lung diseases in the tropics. In: Sharma OP, editor. Tropical lung disease (lung biology in health and disease). New York: Taylor & Francis Group; 2006; 211. pp. 195-239.
63. Vijayan VK. Tropical pulmonary eosinophilia. Curr Opin Pulm Med 2007; 13:428-433.
64. Jiva TM, Israel RH, Poe RH. Tropical pulmonary eosinophilia masquerading as acute bronchial asthma. Respiration 1996; 63:55-58.
65. Cooray JH, Ismail MM. Re-examination of the diagnostic criteria of tropical pulmonary eosinophilia. Respir Med 1999; 93:655-659.
66. Rom WN, Vijayan VK, Cornelius MJ, et al. Persistent lower respiratory tract inflammation associated with interstitial lung disease in patients with tropical pulmonary eosinophilia following treatment with diethylcarbamazine. Am Rev Respir Dis 1990; 142:1088-1092.
67. Oshiro Y, Murayama S, Sunagawa U, et al. Pulmonary dirofilariasis: computed tomographic findings and correlation with pathologic features. J Comput Assist Tomogr 2004; 28:796-800.
68. Miyoshi T, Tsubouchi H, Iwasaki A, et al. Human pulmonary dirofilariasis: a case report and review of the recent Japanese literature. Respirology 2006; 11:343-347.
69. Hisamatsu Y, Ishii H, Kai N, et al. Case of toxocariasis showing migratory nodular shadows with halos. Nihon Kokyuki Gakkai Zasshi 2008; 46:420-424.
70. Bruschi F, Murrell K. Trichinellosis. In: Guerrant R, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice [volume 2]. Philadelphia: Churchill Livingstone; 1999. pp. 917-925.
71. Gomez-Morales MA, Ludovisis A, Amati M, et al. Validation of an ELISA for the diagnosis of human trichinellosis. Clin Vaccine Immunol 2008; 15:1723-1729.
72. Duarte AG, Sattar F, Granwehr B, et al. Disseminated acanthamebiasis after lung transplantation. J Heart Lung Transplant 2006; 25:237-240.
73. Corti M, Villafane MF, Muzzio E, et al. Pulmonary cryptosporidiasis in AIDS patients. Rev Argent Microbiol 2008; 40:106-108.
74. Martinez-Giron R, Esteban JG, Ribas A, Doganci L. Protozoa in respiratory pathology: a review. Eur Respir J 2008; 32:1354-1370.